NRIX
Price
$26.72
Change
-$0.33 (-1.22%)
Updated
Aug 21 closing price
Capitalization
2.77B
47 days until earnings call
Intraday BUY SELL Signals
SKYE
Price
$0.28
Change
-$0.00 (-0.00%)
Updated
Aug 21 closing price
Capitalization
9.92M
74 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NRIX vs SKYE

NRIX vs SKYE Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
NRIX vs. SKYE commentary
Aug 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NRIX is a Hold and SKYE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 23, 2026
Stock price -- (NRIX: $26.72 vs. SKYE: $0.28)
Brand notoriety: NRIX and SKYE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NRIX: 79% vs. SKYE: 291%
Market capitalization -- NRIX: $2.77B vs. SKYE: $9.92M
NRIX [@Biotechnology] is valued at $2.77B. SKYE’s [@Biotechnology] market capitalization is $9.92M. The market cap for tickers in the [@Biotechnology] industry ranges from $138.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NRIX’s FA Score shows that 0 FA rating(s) are green whileSKYE’s FA Score has 0 green FA rating(s).

  • NRIX’s FA Score: 0 green, 5 red.
  • SKYE’s FA Score: 0 green, 5 red.
According to our system of comparison, NRIX is a better buy in the long-term than SKYE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NRIX’s TA Score shows that 4 TA indicator(s) are bullish while SKYE’s TA Score has 4 bullish TA indicator(s).

  • NRIX’s TA Score: 4 bullish, 4 bearish.
  • SKYE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both NRIX and SKYE are a good buy in the short-term.

Price Growth

NRIX (@Biotechnology) experienced а -1.22% price change this week, while SKYE (@Biotechnology) price change was -44.16% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +15.94%, and the average quarterly price growth was +3349.70%.

Reported Earning Dates

NRIX is expected to report earnings on Oct 09, 2026.

SKYE is expected to report earnings on Nov 05, 2026.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NRIX($2.77B) has a higher market cap than SKYE($9.92M). NRIX YTD gains are higher at: 40.854 vs. SKYE (-62.652). SKYE has higher annual earnings (EBITDA): -56.61M vs. NRIX (-343.92M). NRIX has more cash in the bank: 444M vs. SKYE (17.1M). SKYE has less debt than NRIX: SKYE (311K) vs NRIX (58.1M). NRIX has higher revenues than SKYE: NRIX (36.8M) vs SKYE (0).
NRIXSKYENRIX / SKYE
Capitalization2.77B9.92M27,959%
EBITDA-343.92M-56.61M608%
Gain YTD40.854-62.652-65%
P/E RatioN/A3.57-
Revenue36.8M0-
Total Cash444M17.1M2,596%
Total Debt58.1M311K18,682%
FUNDAMENTALS RATINGS
NRIX vs SKYE: Fundamental Ratings
NRIX
SKYE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
52
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3597
P/E GROWTH RATING
1..100
10098
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NRIX's Valuation (46) in the null industry is in the same range as SKYE (52). This means that NRIX’s stock grew similarly to SKYE’s over the last 12 months.

NRIX's Profit vs Risk Rating (100) in the null industry is in the same range as SKYE (100). This means that NRIX’s stock grew similarly to SKYE’s over the last 12 months.

NRIX's SMR Rating (99) in the null industry is in the same range as SKYE (100). This means that NRIX’s stock grew similarly to SKYE’s over the last 12 months.

NRIX's Price Growth Rating (35) in the null industry is somewhat better than the same rating for SKYE (97). This means that NRIX’s stock grew somewhat faster than SKYE’s over the last 12 months.

SKYE's P/E Growth Rating (98) in the null industry is in the same range as NRIX (100). This means that SKYE’s stock grew similarly to NRIX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NRIXSKYE
RSI
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 11 days ago
81%
Bullish Trend 12 days ago
82%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
NRIX
Daily Signal:
Gain/Loss:
SKYE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VIDI40.460.69
+1.73%
Vident International Equity Strategy ETF
IPAC85.160.77
+0.91%
iShares Core MSCI Pacific ETF
ACVT28.760.13
+0.44%
Advent Convertible Bond ETF
IRVH19.19N/A
N/A
Global X Interest Rt Vol & Infl Hdg ETF
FIAX17.35-0.03
-0.17%
Nicholas Fixed Income Alternative ETF

SKYE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with VKTX. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then VKTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
-0.14%
VKTX - SKYE
34%
Loosely correlated
-1.37%
ABOS - SKYE
30%
Poorly correlated
-0.94%
RCKT - SKYE
30%
Poorly correlated
+0.86%
IPSC - SKYE
29%
Poorly correlated
+2.48%
NRIX - SKYE
28%
Poorly correlated
-1.22%
More